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ABSTRACT
T-cell receptor variable  chain (TCRBV) repertoire spectratyping involves the estimation of CDR3 length
distributions for monitoring T-cell receptor diversity and has proven useful for analyses of immune reconsti-
tution and T-cell clonal expansions in graft-versus-host disease (GVHD) and graft-versus-leukemia after
allogeneic stem cell transplantation. We performed a longitudinal spectratype analysis of 23 TCRBV families
in 28 patients who underwent allogeneic T cell–depleted peripheral blood stem cell transplantation. Sixteen
patients subsequently developed acute GVHD. We recently developed statistical methods that bring increased
power and flexibility to spectratype analysis and allow us to analyze TCRBV repertoire development under
appropriately complex statistical models. Applying these methods, we found that patients with acute GVHD
demonstrated TCRBV repertoire development statistically distinct from that repertoire development in
patients without GVHD. Specifically, GVHD patients showed spectratypes indicative of lower diversity and
greater deviation from the spectratypes expected in healthy individuals at intermediate times. Most individual
TCRBV subfamilies had spectratypes statistically distinguishable between GVHD and non-GVHD patients at
6 months after transplantation. These results suggest that the T-cell receptor repertoire perturbations
associated with acute GVHD are widely spread throughout the TCRBV families.
© 2006 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplanta-
ion (allo-SCT) has become the treatment of choice
or a variety of hematopoietic disorders [1]. The
ffectiveness of allo-SCT is often limited by graft-
ersus-host disease (GVHD), which is initiated by
lloreactive T cells in the graft. Various strategies
ave been used to separate GVHD from graft-versus-
eukemia activities. An immunosuppressive regimen
dministered in the months after allo-SCT is the most
fﬁcient preventive treatment but remains only par-
ially effective [2]. T-cell depletion can prevent GVHD
3-5] but increases the risk of graft rejection, leukemic
elapse, and opportunistic infection [6,7]. The selec- S
B&MTive depletion of alloreactive T cells, as an adaptation
f total T-cell depletion, has effectively prevented
VHD without impairing other immune functions by
argeting activation markers after host-reactive T cells
re activated in vitro [8-12]. Only a few of these
trategies, however [13,14], have been explored in
uman trials so far because of the complexity of the
rocesses involved. In many of these approaches, im-
une reconstitution is an important area for contin-
ed study and monitoring.
The T-cell receptor (TCR) repertoire has been
tudied in the immune recovery processes of patients
ith a variety of hematopoietic disorders after allo-
CT. Analysis of the complementarity-determining
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3egion 3 (CDR3) via T-cell receptor variable  chain
TCRBV) spectratyping [15] could elucidate the
lonal expansion of T cells associated with graft-ver-
us-leukemia and GVHD. In this study, we analyzed
hanges in each of the subfamilies of the TCRBV
epertoire from peripheral blood and compared the
xtent of perturbation in each TCRBV family be-
ween patients with and without GVHD. We investi-
ated the relative changes over time in the TCRBV
epertoire in these patients.
ATERIALS AND METHODS
atients and Cells
Blood samples were obtained before transplantation
nd at regular intervals after transplantation from 28
atients who underwent allogeneic T cell–depleted pe-
ipheral blood stem cell transplantation (allo-PBSCT)
rom February 2000 to March 2003 at Duke Univer-
ity Medical Center after informed consent for sample
ollection. All donors and recipients were related.
wenty-six donor-recipient pairs were matched for
LA, and 2 pairs in the GVHD group were mis-
atched (5/6 and 4/6). Peripheral blood mononuclear
ells (PBMCs) were prepared by density gradient sed-
mentation by using Ficoll-Hypaque, cryopreserved in
edium with 10% dimethyl sulfoxide, and stored
t 190°C until analysis. Jurkat cells were cultured in
PMI-1640 containing 10% fetal calf serum and
erved as templates for reverse transcriptase-polymer-
se chain reaction–positive control.
DR3 Size Spectratyping and Statistical Analysis
CDR3 size spectratyping was used to analyze the
CR repertoire. RNA was extracted from 0.5 to 5 
06 PBMCs and Jurkat cells by using an RNeasy Mini
it (Qiagen, Hilden, Germany). First-strand comple-
entary DNA (cDNA) was generated from 1.5 g of
otal RNA by using random hexamer primer (Pro-
ega, Madison, WI) and Moloney murine leukemia
irus reverse transcriptase (Gibco BRL Carlsbad, CA)
n 30 L of reaction. The quality of the cDNA was
etermined by careful examination of the product of
he housekeeping gene glyceraldehyde 3-phosphate
ehydrogenase (G3PDH). PCR was performed using
panel of 23 different TCRBV primers and 1 C
rimer, which have been described previously [15].
he TCRBV8 and C primers were used in the PCR
mpliﬁcation for Jurkat cells. Each TCRBV segment
as ampliﬁed from 1 L of the cDNA in a 20-L
eaction. The ﬁnal mixture contained 0.5 mol/L of
ach TCRBV primer, 0.5 mol/L C primer, 0.25
mol/L deoxynucleoside triphosphate, and 0.025 U
f Taq polymerase (Applied Biosystems, Foster City,
A). Ampliﬁcation was performed in a DNA thermal
ycler (Gene Amp PCR system 9700, PE Applied m
36iosystems, Foster City, CA). After 30 seconds of
enaturation at 94°C, 40 cycles consisting of denatur-
tion at 94°C for 1 minute, annealing at 60°C for 45
econds, and extension at 72°C for 45 seconds were
erformed. After the 40 cycles of PCR, an additional
xtension at 72°C lasted 15 minutes.
Two microliters of the beta variable (BV)-C PCR
roducts was subjected to 5 cycles of elongation (runoff)
eaction with a nested carboxyﬂuorescein-labeled C
rimer. The runoff products were then subjected to
lectrophoresis on an ABI sequencer (PE Applied Bio-
ystems) in the presence of ﬂuorescent size markers.
nitial analysis was performed with the Genescan soft-
are provided by the manufacturer (Applied Biosys-
ems). Products differing in size were thus separated and
uantitated as discrete peaks. Because the positions of
he BV and C primers were ﬁxed, the length of distri-
ution observed in the BV-C products directly re-
ected the CDR3 lengths as determined by the rear-
angement of the V-D and D-J gene segments and the
andomly inserted nucleotides. The TCR spectratype in
ealthy adult subjects displays an average of 8 to 10 peaks
er subfamily, corresponding to in-frame transcripts,
ontained within a symmetric, bell-shaped, or quasi-
aussian distribution. Alterations of the normal reper-
oire result in measurable deviations from this ideal dis-
ribution.
Spectratypes were analyzed by using the methods
eveloped by 2 of the co-investigators [16] and imple-
ented online for public use as SpA: Spectratype Anal-
sis [17]. An abbreviated description is as follows: Ge-
escan provides tables of peak heights, central locations,
nd areas. These tables are processed in SpA to assign
ach reported output peak to an integer-valued CDR3
ength by using a maximum-likelihood method that ac-
ounts for random single-nucleotide additions (as is
nown to occur with spectratyping), as well as among-
un stochastic variability in electrophoretic mobility and
ithin-run random error variation. More than 1 re-
orted peak may be assigned to each CDR3 length; the
elative frequency assigned to any 1 CDR3 is the sum of
he areas under the associated reported peaks. For each
CRBV family, a reference distribution was estimated
rom spectratypes performed independently on periph-
ral blood from each of 5 individual healthy volunteers
ho did not undergo transplantation. The estimation of
hese distributions was performed by maximum likeli-
ood. For each observed spectratype distribution, we
omputed the Kullback-Leibler divergence (DKL) be-
ween it and the corresponding reference distribution
16]. The DKL, which we will from here on refer to as
imply the divergence, quantiﬁes the departure of each
bserved CDR3 length distribution from the corre-
ponding reference distribution. The divergences for
ach TCRBV, each patient, and each available time after
ransplantation were subjected to logarithmic transfor-
ation to regularize the variance and were collected for
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Bnalysis by linear modeling by using the S-plus software
ackage (version 6.1; Insightful Corp., Seattle,WA).We
t a series of linear models with diagnosis, time, TCRBV
amily, and GVHD as predictors (independent vari-
bles). Because of the small number of distinct sampling
imes, time was treated as a categorical variable.
mmunologic Recovery
Immune recovery was analyzed before transplanta-
ion and at 6 weeks and 3, 6, and 12 months after
ransplantation. PBMCs were stained with ﬂuorescent-
abeled monoclonal antibodies and analyzed by ﬂow cy-
ometry. The data were analyzed by using Flow Jo
oftware (Becton Dickison, Franklin Lakes, NJ). Mono-
lonal antibodies used in this study included anti-CD3,
CD4, and -CD8. The Student t test was used to analyze
he difference in cell populations between patients with
cute GVHD and without GVHD.
ESULTS
atient Characteristics
Twenty-eight patients’ characteristics are described
n Table 1. The median age was 46 years (range, 24-61
able 1. Patient Characteristics
Patient
No. Age (y)/Sex Diagnosis Preparative
001 24/M Thalassemia Mini, Cam/F
013 37/F Aplastic anemia Mini, Cam/F
020 60/M MCl Mini, Cam/F
024 43/M ALL Full, TBI/Cy
033 40/F AML Mini, Cam/F
061 41/M CML Full, busulfa
090 61/M Renal cell cancer Mini, Cam/F
0103 25/F ALL Full, TBI/Cy
0164 47/F MDS Mini, Cam/F
0165 57/M MCl Mini, Cam/F
0121 50/F Myelofibrosis Mini, Cam/F
0212 39/F Breast cancer II Mini, Cam/F
010 47/F Breast cancer Met. IV Mini, Cam/F
012 59/F AML Mini, Cam/F
014 54/F Breast cancer Met. IV Full, busulfa
021 66/F MDS Mini, Cam/F
023 45/F ALL Full, TBI/VP
031 44/M MDS Mini, Cam/F
070 45/M Renal cell cancer Mini, Cam/F
072 51/F MDS Mini, Cam/F
0101 61/M MDS Mini, Cam/F
0102 44/F Myeloma Mini, Cam/F
0116 52/M CLL Mini, Cam/F
0118 45/M Renal cell cancer Mini, Cam/F
0120 45/M CML Full, busulfa
0162 50/F Breast cancer Met. IV Mini, Cam/F
0166 41/F NHL Mini, Cam/F
0210 45/F AML Mini, Cam/F
am indicates campath; Flu, ﬂudarabine; Cyc, cyclophosphamide
irradiation; Mini, nonmyeloablative; Full, myeloablative; VP1
leukemia; CML, chronic myeloid leukemia; MDS, myelodys
Hodgkin’s lymphoma; MCL, mantle cell lymphoma; CMV statu
cancer stage II, breast cancer metastatic, stage IV.
B&MTears). Five patients received allo-PBSCT for myelodys-
lastic syndromes, 4 for breast cancer, 3 for acute
yeloid leukemia, 3 for acute lymphocytic leukemia, 3
or renal cell cancer, 2 for chronic myelogenous leu-
emia, 2 for mantle cell lymphoma, and 1 each with
halassemia, aplastic anemia, myeloﬁbrosis, myeloma,
hronic lymphocytic leukemia, and non-Hodgkin’s lym-
homa. Sixteen patients had acute GVHD grade II or
reater affecting the skin, gut, or both. Seven of the 16
atients developed chronic GVHD. Nineteen patients
ad a positive cytomegalovirus (CMV) DNA test.
DR3 Size Analysis of Normal Human PBMCs
Figure 1 shows a representative CDR3 size distribu-
ion from normal individual human PBMCs. A total of
3 of 24 TCRBV-C subfamilies displayed mostly bell-
haped, quasi-gaussian size distributions of 8 to 10 iden-
iﬁable peaks spaced by 3 nucleotides. TCRBV 13B gave
very weak signal in most PBMCs. TCRBV 24 some-
imes failed to yield interpretable proﬁles. Panel
CRBV 13A is poorly expressed in most individuals.
nstead of this panel, a PCR-positive control, Jurkat
ells’ cDNA, were run with TCRBV8 and C primers,
howing 2 discrete peaks. Overall, the patterns observed
en GVHD Prophylaxis
Acute
GVHD
Chronic
GVHD
CMV
Status
CSA/MMF — — 
— — 
— — 
— — 
— — 
— — 
— — 
-C CSA — — 
— — 
— — 
— — 
— — 
III — 
II — 
CSA IV — 
II  skin 
CSA/prednisone III  skin 
II — 
CSA III — 
II — 
IV  
II — 
II  skin 
III  skin & gut 
CSA/methotrexate IV — 
II — 
III  skin 
III  skin 
, cyclosporin A; MMF, mycophenolate mofetil; TBI, total body
oside; ALL, acute lymphoblastic leukemia; AML, acute myeloid
syndrome; CLL, chronic lymphoblastic leukemia; NHL, non-
ent’s DNA by hybrid capture; ARA-C, cytosine arabinoside; breastRegim
lu/Cyc
lu/Cyc
lu/Cyc
c
lu/Cyc
n/Cyc
lu/Cyc
c/ARA
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
n/Cyc
lu/Cyc
16
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
n/Cyc
lu/Cyc
lu/Cyc
lu/Cyc
; CSA
6, etop
plastic
s, pati337
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3n PBMCs from healthy humans were reproducible from
ne individual to another, but deviations from the usual
aussian-like proﬁles could be found in runoff proﬁles.
DR3 Size Analysis in Acute GVHD after
llo-PBSCT
The changes in the TCRBV gene repertoire were
igure 1. CDR3 size distribution patterns in PBMCs from individu
mpliﬁed by PCR with 23 pairs of TCRBV- and C-speciﬁc primer
 primer and loaded to electrophoresis on an automated DNA seq
f the Immunoscope software package (PE Applied Biosystems).nalyzed at different time points (days 42, 90, 180, and a
3860 after allo-PBSCT). The CDR3 size distribution
n most TCRBV transcripts analyzed from non-
VHD patients demonstrated the expected bell-
haped patterns of more than 5 peaks from 6 weeks
fter transplantation. Moreover, the peak numbers in
ost families remained stable. In contrast, the major
lternation of CDR3 size distribution in patients with
thy humans. Total RNA from PBMCs was reverse-transcribed and
CR product was further copied in runoff reactions by a ﬂuorescent
. The size and intensity of each peak were determined with the helpal heal
s. The P
uencercute GVHD was the modiﬁcation of the regular
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Baussian distribution by 1 or several peaks. This alter-
tion in some BV families did not improve by 6
onths or even by 1 year. This phenomenon may be
ue to 1 or several clonal T-cell expansions. Figure 2
hows the repertoire diversity as a histogram in rep-
esentative patients with and without GVHD. The
eak number in most TCRBV subfamilies of acute
VHD patients was 1 to 4, and some of them did not
emonstrate restoration until 2 years (Figure 2A). In
ontrast, TCRBV subfamily peak numbers in non-
VHD patients ranged from 5 to 10 peaks even at
arly time points after transplantation. Furthermore,
ost expressed TCRBV gene subfamilies displayed a
elatively stable picture at the following time point
Figure 2B). Meanwhile, some BV families showed a
light decrease in the repertoire complexity by 6
onths compared with 6 weeks, such as TCRBV3, 4,
, 12, 16, and 23. This may be relative to the complex
linical situation that occurs during the transplanta-
ion course. Infections are a common complication
fter transplantation.
To compare the extent of perturbation that is
ttributable to the difference in GVHD status among
atients, we ﬁrst performed a stepwise regression,
tepping in both directions, by using diagnosis, age,
ex, GVHD status, TCRBV family, and days after
ransplantation (as a categorical variable), as well as
he estimable interactions, as the possible predictor
ariables for the log of the divergence as the response.
he best model found excluded age and sex altogether
nd used time, TCRBV family, diagnosis, GVHD
tatus, and the interactions between GVHD and time
nd between GVHD and TCRBV family as predic-
ors. We conﬁrmed these results with direct likelihood
atio tests and, in particular, found that the omission
f GVHD was rejected quite soundly (P  106) and
hat omission of the TCRBV-GVHD interaction was
lso rejected (P  103).
Figure 3A shows the effects of GVHD status over
ime by plotting the components of the predicted
esponse attributable to GVHD and time only. This
lot allows for the appropriate correction for diagno-
is while averaging over TCRBV families. Note that
he GVHD patients and the non-GVHD patients are
ndistinguishable before transplantation and then
gain at 6 months after transplantation. At intermedi-
te times, the divergence in the GVHD group was
igniﬁcantly higher than that in the non-GVHD
roup, corresponding to greater perturbation from
he healthy proﬁle and decreased diversity in the
VHD group. We similarly examined the contribu-
ions to the GVHD effect from each of the TCRBV
amilies (Figure 3B). This ﬁgure shows the 95% con-
dence intervals for the TCRBV-GVHD interaction
erms. Although these terms differ from each other
tatistically, 14 of 23 families have nonzero coefﬁ-
ients, and all of these are positive, thus indicating h
B&MTmaller diversity in the GVHD patients for all of these
amilies. Altogether, 21 of 23 families had a positive
VHD-TCRBV coefﬁcient.
These results are suggestive of multiple antigen-
riven T-cell clonal expansions, with greater magni-
udes of such expansions in GVHD patients compared
ith non-GVHD patients. Figure 4 further demon-
trates the dynamic changes of perturbed TCRBV
amilies 7, 11, 15, 16, 17, and 23 in representative
atients after transplantation.
ymphocyte Subset Reconstitution
fter Transplantation
To better understand the changes in the TCRBV
epertoire between patients with and without acute
VHD after transplantation, we evaluated the recon-
titution of T lymphocytes and their subsets, includ-
ng CD3, CD4, and CD8, by immunophenotypic
nalysis of PBMCs at the same serial time points after
ransplantation. Table 2 lists the results of the lym-
hocyte recovery after transplantation. Both the lym-
hocyte count and the CD8 cell count were statistically
ower in the GVHD group than in the non-GVHD
roup.
ISCUSSION
Mature /T cells in the graft play a major role in
he induction of GVHD. Through their receptors, T
ells recognize a subset of host peptides, called minor
istocompatibility antigens (miHAs), which are de-
ived from the expression of polymorphic genes that
istinguish host from donor [18]. Each TCR molecule
ncludes a variable and a constant region. CDR3 of the
V chain of the TCR forms the contact site for bind-
ng peptides in HLA complexes and plays a key role in
eﬁning the speciﬁcity of antigen recognition. The
uman genome contains 52 functional BV segments
elonging to 24 subfamilies, 2D and 13 J segments
hat undergo variable, diversity, joining regions (VDJ)
earrangements to express a V region [19,20]. This
ombinatorial diversity is greatly enhanced by random
nsertion and deletion of junctional ﬂexibility and N-
egion nucleotide additions. The generated size het-
rogeneity of the CDR3 region during rearrangement
ontributes to the shaping of the TCR repertoire.
According to PCR ampliﬁcation of the BV CDR3
egion, healthy individuals demonstrate highly diverse
nd polyclonal TCR repertoires with a typical quasi-
aussian distribution of approximately 8 to 10 different
izes for each BV region separated by 3 nucleotides.
trong immune responses, such as GVHD, organ trans-
lant rejection, and infection, are associated with oligo-
lonal or monoclonal CDR3 patterns in the peripheral
lood and in the affected tissues [21-23]. It is difﬁcult,
owever, to simply compare the extent of variability of
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VB1 VB2 VB3 VB4 VB5 VB6A VB6B VB7 VB8 VB9 VB11 VB12 VB13B VB14 VB15 VB16 VB17 VB18 VB20 VB21 VB22 VB23 VB24
BMT-0116  day-42
0
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0
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10
VB1 VB2 VB3 VB4 VB5 VB6A VB6B VB7 VB8 VB9 VB11 VB12 VB13B VB14 VB15 VB16 VB17 VB18 VB20 VB21 VB22 VB23 VB24
BMT-0116 6-month
0
5
10
VB1 VB2 VB3 VB4 VB5 VB6A VB6B VB7 VB8 VB9 VB11 VB12 VB13B VB14 VB15 VB16 VB17 VB18 VB20 VB21 VB22 VB23 VB24
BMT-0116 1-year
0
5
10
VB1 VB2 VB3 VB4 VB5 VB6A VB6B VB7 VB8 VB9 VB11 VB12 VB13B VB14 VB15 VB16 VB17 VB18 VB20 VB21 VB22 VB23 VB24
BMT-0116 2-year
igure 2. A representative composite spectratyping of the TCRBV gene at serial time points after allo-PBSCT. TCRBV subfamilies are shown
n the x-axis, and peak numbers per family are shown on the y-axis. A, TCRBV repertoire in a patient with acute GVHD. The peak numbers
n most of the TCRBV subfamilies were less than 4. B, TCRBV repertoire in a patient without acute GVHD. The peak numbers in most of
he TCRBV subfamilies were more than 5.
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3CR repertoires among samples. Therefore, in this
tudy we introduced a novel method of analysis by using
he SpA software package. This package allows for anal-
sis of the similarity to an expected quasi-gaussian dis-
ribution in each subfamily of TCR repertoires. The
hanges of DKL values reﬂect the extent of perturbation
n the TCR repertoire (ie, how far away it is from the
xpected distribution). When the observed CDR3 pat-
ern is identical to the reference distribution, the DKL
alue vanishes; otherwise, the DKL value is positive. A
igh DKL value indicates a greater perturbation from the
redicted reference distribution.
igure 3. Comparison of the extent of perturbation in the TCRBV
epertoire between groups with and without GVHD from 6 weeks to
months after transplantation. A, Divergence attributable to differ-
nces in GVHD status as a function of time since transplantation,
stimated as described in the text (triangles, GVHD; circles, no
VHD). Corrected refers to the subtraction of components attributable
o predictors other than GVHD and time. Increasing divergence is
quivalent to greater perturbation from the healthy proﬁle and de-
reased diversity. Note that the 2 populations are indistinguishable
efore transplantation and again at 6 months after transplantation.
rror bars represent 95% conﬁdence intervals. B, The 95% conﬁdence
ntervals for the corrected mean difference between GVHD and non-
VHD patient divergences, as described in the text. Corrected again
efers to the subtraction of components of predictors other than
CRBV and GVHD. Those conﬁdence intervals that do not include
he origin correspond to hypothesis tests in which the null hypothesis,
hat the true mean difference is 0, was rejected.The data presented here demonstrate that some c
42V subfamilies had clearly less complexity or even no
epertoire detected in most recipients examined early
fter transplantation. These data were consistent with
he results of previous studies [24-26]. This low level
f complexity and oligoclonality may reﬂect an imbal-
nce of the TCR repertoire secondary to the alter-
tions of environmental conditions, a simple delay in
he reappearance of some BV subfamily speciﬁcities,
r both [27]. In this study, the data suggest that the
ower complexity might be caused by limited T-cell
ecovery from the donor peripheral blood stem cell
ource (Table 2), because almost all of the patients in
his study had more than 85% donor cells in their
himerism studies (data not shown), although we can-
ot exclude the possible contributions of residual host
ells. We also did not separate the T cells into CD4
nd CD8 subsets, so the relative perturbation of each
f these subfamilies cannot be determined from this
tudy. Most patients in both groups reactivated human
MV, but none of them developed CMV infection
Table 1). Therefore, the inﬂuence of CMV antigen-
mia on the recovery of the TCR repertoire was
alanced in the groups with and without GVHD.
This study further showed that patients with acute
VHD demonstrated TCRBV repertoire develop-
ent statistically distinct from the repertoire develop-
ent in patients without GVHD. TheGVHDpatients
nd the non-GVHD patients were indistinguishable be-
ore transplantation and then again at 6 months after
ransplantation. At intermediate times, the divergence
n the GVHD group was signiﬁcantly higher than that
n the non-GVHD group, corresponding to greater
erturbation from the healthy proﬁle and decreased
iversity in the GVHD group. Most individual
CRBV subfamilies had spectratypes that were statis-
ically distinguishable between GVHD and non-
VHD patients at 6 months after transplantation.
hese results are suggestive of multiple antigen-
riven T-cell clonal expansions, with greater magni-
udes of such expansions in GVHD patients compared
ith non-GVHD patients. None of the patients was
n relapse at the time of sample collection, but some of
he patients did develop chronic GVHD in the acute
VHD group. To allow a better understanding of
hether chronic GVHD enhances the perturbation of
he repertoire, we performed statistical analyses be-
ween patients with only acute GVHD and those who
eveloped chronic GVHD. The results showed dis-
inguishable spectratypes (P  .02). These data sug-
est that chronic GVHD does enhance the perturba-
ion of the repertoire. These ﬁndings further conﬁrm
he observation that oligoclonal expansions of
CRBV families occur frequently and often correlate
ith clinical events of GVHD [21,28]. A recent study
y Tsutsumi et al. [25] also demonstrated lower
CRBV complexity in patients with chronic GVHD
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Bata suggest that the expansion of these T-cell sub-
amilies may have been driven in response against the
atient’s miHAs [29,30].
Human miHAs are recognized in the context of
ajor histocompatibility complex molecules [30], and
ytotoxic T lymphocytes against miHAs have been
mplicated in GVHD [28]. Skin is frequently involved
n GVHD, and T cells inﬁltrating a GVHD target
rgan are likely to be implicated in a graft-versus-host
eaction. Many perturbed TCRBVs from PBMCs in
his study (BV 2, 6, 16, 17, and 23) have been reported
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he skin with GVHD, they have been observed in
eripheral blood in other studies [25,27,31,32]. This
ifference may reﬂect the possibility that T cells ini-
ially expanded in blood may selectively home to the
kin because of the high level of adhesion molecules,
hemokines, or major histocompatibility complex
olecule expression [33,34]. To further understand
he T-cell differentiation pathway, a TCR excision
ircle assay on PBMCs was performed. All TCR ex-
ecipients with or without acute GVHD at serial time points after
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3p to 6 months after transplantation except for 2
atients without GVHD (data not shown). These re-
ults indicate that the circulating T cells were derived
rom donor mature T cells, a thymic-independent
athway.
In conclusion, this study demonstrates that the
xtent of perturbed T-cell repertoires is signiﬁcantly
igher in PBMCs of patients with acute GVHD com-
ared with those without GVHD during the ﬁrst 6
onths after allo-PBSCT. Moreover, the TCR rep-
rtoire perturbations associated with acute GVHD
ere widely spread throughout the TCRBV families.
lthough we cannot rule out the importance of the
teroids used to treat GVHD on the basis of the
bserved difference between the TCR repertoires in
VHD-affected and -nonaffected subjects, it seems
ikely that such steroids would suppress the outgrowth
f rogue T-cell clones and, thus, contribute to a more
ormal-looking TCR spectratype, which is the oppo-
ite of what is observed. Although the spectratype
echnique allows a precise measurement of the CDR3
egion and the ability to distinguish different TCR
lonotypes, further studies are needed to determine
hether the perturbed repertoires detected in vivo
orrespond to T-cell clones with speciﬁc cytotoxicity
gainst miHAs. Elimination of such clones from the
raft inoculum could prevent GVHD while conserv-
ng graft-versus leukemia responses.
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